Abstract:Autoimmune diseases are collectively addressed as chronic conditions initiated by the loss of one's immunological tolerance, where the body treats its own cells as foreigners or self-antigens. These hay-wired antibodies or immunologically capable cells lead to a variety of disorders like rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis and recently included neurodegenerative diseases like Alzheimer's, Parkinsonism and testicular cancer triggered T-cells induced autoimmune response in testes and brain. Conventional treatments for autoimmune diseases possess several downsides due to unfavourable pharmacokinetic behaviour of drug, reflected by low bioavailability, rapid clearance, offsite toxicity, restricted targeting ability and poor therapeutic outcomes. Novel nanovesicular drug delivery systems including liposomes, niosomes, proniosomes, ethosomes, transferosomes, pharmacosomes, ufasomes and biologically originated exosomes have proved to possess alluring prospects in supporting the combat against autoimmune diseases. These nanovesicles have revitalized available treatment modalities as they are biocompatible, biodegradable, less immunogenic and capable of carrying high drug payloads to deliver both hydrophilic as well as lipophilic drugs to specific sites via passive or active targeting. Due to their unique surface chemistry, they can be decorated with physiological or synthetic ligands to target specific receptors overexpressed in different autoimmune diseases and can even cross the blood-brain barrier. This review presents exhaustive yet concise information on the potential of various nanovesicular systems as drug carriers in improving the overall therapeutic efficiency of the dosage regimen for various autoimmune diseases. The role of endogenous exosomes as biomarkers in the diagnosis and prognosis of autoimmune diseases along with monitoring progress of treatment will also be highlighted.

Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases

Cationic nanoparticles-based approaches for immune tolerance induction in vivo

Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance

Tolerogenic Nano-/Microparticle Vaccines for Immunotherapy.

Nanomaterials for antigen-specific immune tolerance therapy

Tolerogenic Vehicles of Antigens in the Antigen-Specific Immunotherapy for Autoimmunity

Peptide-Conjugated Nanoparticles Reduce Positive Co-stimulatory Expression and T Cell Activity to Induce Tolerance

212 Co-delivery of Vitamin D3 and Antigens by Nanoparticles Enhances Immune Tolerance Through Induction of Tolerogenic Dendritic Cells in Vivo

Evolution of nanomedicines for the treatment of autoimmune disease: From vehicles for drug delivery to inducers of bystander immunoregulation

Progress in Nanoparticle-Based Regulation of Immune Cells.

Targeting Lymphoid Tissues to Promote Immune Tolerance

Biocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases

Liver-Targeting Nanoplatforms for the Induction of Immune Tolerance

Antigen-specific nanoparticle tolerance treatment actively induces both FoxP3- and IL-10-dependent regulatory mechanisms

Polymer Nanotherapeutics to Correct Autoimmunity

Therapeutic Potential of Tolerance-Based Peptide Vaccines in Autoimmune Diseases.

Nanoparticle-neutrophils interactions for autoimmune regulation

Antigen‐specific Mrna Lipid Nanoparticle Platforms for the Prevention and Treatment of Allergy and Autoimmune Diseases

Dendritic Cell Vaccine Design: Strategies for Eliciting Peripheral Tolerance as Therapy of Autoimmune Diseases

Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis

Antigen-specific nanomedicines for the treatment of autoimmune disease: target cell types, mechanisms and outcomes